Text Size

Long-term Effect of Lanthanum Carbonate on Bone

This study has been completed.
Sponsor:
Information provided by:
Shire Development LLC
ClinicalTrials.gov Identifier:
NCT00557323
First received: November 12, 2007
Last updated: May 19, 2011
Last verified: May 2011
History of Changes
  Purpose

Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.


Condition
Hyperphosphatemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309

Further study details as provided by Shire Development LLC:

Primary Outcome Measures:
  • Number of Study-emergent Bone-related Adverse Events (AEs) [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of Study-emergent Deaths [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 34
Study Start Date: August 2005
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any patients from study SPD405-309 who were exposed to lanthanum carbonate

Criteria

Inclusion Criteria:

  • Any patient who had exposure to lanthanum carbonate in SPD405-309
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00557323

Locations
United States, California
Imperial care Dialysis Center
Lynwood, California, United States, 90262
Barnett Research and Communications Medical Group
Torrance, California, United States, 90503-4100
United States, Massachusetts
Western new England Renal & Transplant Associates
Springfield, Massachusetts, United States, 01107
United States, Ohio
Mercy Medical Center
Canton, Ohio, United States, 44708
United States, Rhode Island
Hypertension & Nephrology, Inc.
Providence, Rhode Island, United States, 02904
United States, Tennessee
Nephrology Associates, PC
Nashville, Tennessee, United States, 37205
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05401
United States, Virginia
Nephrology Associates, PC
Richmond, Virginia, United States, 23226-2022
Germany
Bad Koenig, HE, Germany, 64732
KfH Zentrum
Aachen, Germany, 52074
Dialysenzentrum
Bad Homburg, Germany, 61348
KfH Dialysezentrum
Berlin, Germany, 12045
KfH Kuratorium duer Dialyse und Nierentransplanta Dialysezentrum Moabit
Berlin, Germany, 10559
Dialysezentrum Barmbek
Hamburg, Germany, 22297
Dialysepraxis Altona
Hamburg, Germany, 22767
KfH Dialysezentrum
Rosenheim, Germany, 83022
United Kingdom
Addenbrooke's Hospital
Cambridge, United Kingdom, CAMBS CB2 2QQ
St. Helier Hospital
Carshalton, United Kingdom, GT LON SM5 1AA
Manchester Royal Infirmary
Manchester, United Kingdom, GT MAN M13 9WL
Sponsors and Collaborators
Shire Development LLC
Investigators
Principal Investigator: Alastair Hutchison, MD Manchester Royal Infirmary, Manchester, UK
  More Information

No publications provided

Responsible Party: Timothy Whitaker, M.D., Shire Pharmaceutical
ClinicalTrials.gov Identifier: NCT00557323     History of Changes
Other Study ID Numbers: SPD405-402
Study First Received: November 12, 2007
Results First Received: May 19, 2011
Last Updated: May 19, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hyperphosphatemia
Phosphorus Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 16, 2013